Sapanisertib (also known as MLN0128, INK128 and TAK-228) is an
experimental small molecule
inhibitor of mTOR which is administered orally. It targets both
mTORC1 and
mTORC2.
Developed by
Millennium Pharmaceuticals, and is in
phase II clinical trials for
breast cancer,
endometrial cancer
Endometrial cancer is a cancer that arises from the endometrium (the lining of the uterus or womb). It is the result of the abnormal growth of cells that have the ability to invade or spread to other parts of the body. The first sign is most o ...
,
glioblastoma,
renal cell carcinoma, and
thyroid cancer. The drug has been well
tolerated by patients with advanced solid tumours in
Phase I trials
The phases of clinical research are the stages in which scientists conduct experiments with a health intervention to obtain sufficient evidence for a process considered effective as a medical treatment. For drug development, the clinical phases ...
.
References
{{reflist
Experimental cancer drugs
Benzoxazoles
Isopropyl compounds
Amines